



Lorlatinib

Lungenkarzinom, nicht-kleinzellig (NSCLC) » ALK+ » nach Vorbehandlung

Empfehlungen der Fachgesellschaft zum Einsatz neuer Arzneimittel

Herausgeber

DGHO Deutsche Gesellschaft für Hämatologie und
Medizinische Onkologie e.V.
Alexanderplatz 1
10178 Berlin

Geschäftsführender Vorsitzender: Prof. Dr. med. Lorenz Trümper

Telefon: +49 (0)30 27 87 60 89 - 0
Telefax: +49 (0)30 27 87 60 89 - 18

info@dgho.de
www.dgho.de

Ansprechpartner

Prof. Dr. med. Bernhard Wörmann
Medizinischer Leiter

Quelle

www.onkopedia.com

Die Empfehlungen der DGHO für die Diagnostik und Therapie hämatologischer und onkologischer Erkrankungen entbinden die verantwortliche Ärztin / den verantwortlichen Arzt nicht davon, notwendige Diagnostik, Indikationen, Kontraindikationen und Dosierungen im Einzelfall zu überprüfen! Die DGHO übernimmt für Empfehlungen keine Gewähr.

Inhaltsverzeichnis

1 Lorlatinib, NSCLC, ALK+, previously treated	2
--	----------

Lorlatinib

Dokument: Fact Sheet

Spezifizierung: Lungenkarzinom, nicht-kleinzellig (NSCLC) » ALK+ » nach Vorbehandlung

Stand: Juli 2021

1 Lorlatinib, NSCLC, ALK+, previously treated

Lorlatinib, NSCLC, ALK+, previously treated																								
onkopedia		Facts	Appraisal																					
Parameter	Results¹⁴	HR¹⁵	p value																					
PFS ³	5.6 - 7.3																							
OS ⁵	62.0 - 67.7																							
<div style="border: 1px solid black; border-radius: 50%; padding: 2px; display: inline-block;">EU Approval 2019</div>																								
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%;"></td> <td style="width: 10%; text-align: center;">5</td> <td style="width: 10%; text-align: center;">4</td> <td style="width: 10%; text-align: center;">3b</td> <td style="width: 10%; text-align: center;">3a</td> <td style="width: 10%; text-align: center;">2c</td> <td style="width: 10%; text-align: center;">2b</td> <td style="width: 10%; text-align: center;">2a</td> <td style="width: 10%; text-align: center;">1b</td> <td style="width: 10%; text-align: center;">1a</td> </tr> <tr> <td>Evidence (LoE)</td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> </table>					5	4	3b	3a	2c	2b	2a	1b	1a	Evidence (LoE)										
	5	4	3b	3a	2c	2b	2a	1b	1a															
Evidence (LoE)																								
<table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 20%;"></td> <td style="width: 20%; text-align: center;">1</td> <td style="width: 20%; text-align: center;">2</td> <td style="width: 20%; text-align: center;">3</td> <td style="width: 20%; text-align: center;">4</td> <td style="width: 20%; text-align: center;">5</td> </tr> <tr> <td>Clinical benefit (ESMO MCBS)</td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: yellow;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> </table> <p> ■ curative ■ non-curative </p>					1	2	3	4	5	Clinical benefit (ESMO MCBS)														
	1	2	3	4	5																			
Clinical benefit (ESMO MCBS)																								
Patients ALK+, previously treated with ≥2 ALKi Trial Phase 2 Randomisation - : - N¹ 111 New Therapy Lorlatinib Control Publication DOI:10.1016/S1470-2045(18)30649-1 DOI:10.1200/JCO.2018.78.7994		Additional benefit (G-BA) <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 15%;"></td> <td style="width: 15%; text-align: center;">lower</td> <td style="width: 15%; text-align: center;">proven</td> <td style="width: 15%; text-align: center;">not quantifiable</td> <td style="width: 15%; text-align: center;">not minor</td> <td style="width: 15%; text-align: center;">considerable</td> <td style="width: 15%; text-align: center;">major</td> </tr> <tr> <td>suitable for immunochemotherapy</td> <td style="background-color: #cccccc;"></td> <td style="background-color: black;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> <tr> <td>not suitable for immunochemotherapy</td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> <td style="background-color: #cccccc;"></td> </tr> </table>			lower	proven	not quantifiable	not minor	considerable	major	suitable for immunochemotherapy							not suitable for immunochemotherapy						
	lower	proven	not quantifiable	not minor	considerable	major																		
suitable for immunochemotherapy																								
not suitable for immunochemotherapy																								

Legende:

¹ N - number of patients

³ PFS - progression-free survival in months

⁵ OS - overall survival in months

¹⁴ results for control, results for new therapy

¹⁵ hazard ratio for new therapy